Under the agreement, Affitech receives a license to use Xoma’s bacterial cell expression technology for developing antibody products. Affitech also receives an option for the production of antibodies under Xoma’s intellectual property.
In return, Xoma will use Affitech’s naive antibody library for target research and discovery purposes as well as the development and commercialization of selected antibodies.
In addition, Affitech has agreed to build patient-derived libraries for Xoma and discover new antibodies against Xoma targets exploiting Affitech’s patient libraries.
“Through the addition of Affitech’s naive antibody library, Xoma now provides a single point of access to the world’s largest collection (seven) of the leading commercially available antibody phage display libraries,” said Dr Robert Gundel, vice president, scientific corporate development, Xoma.